JPS6253920A - 医薬 - Google Patents

医薬

Info

Publication number
JPS6253920A
JPS6253920A JP61147996A JP14799686A JPS6253920A JP S6253920 A JPS6253920 A JP S6253920A JP 61147996 A JP61147996 A JP 61147996A JP 14799686 A JP14799686 A JP 14799686A JP S6253920 A JPS6253920 A JP S6253920A
Authority
JP
Japan
Prior art keywords
group
alkyl group
methyl
hydrogen atom
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP61147996A
Other languages
English (en)
Japanese (ja)
Other versions
JPH0324447B2 (enExample
Inventor
マイクル、ブライアン、タイアース
イアン、ハロルド、コーテス
デイビッド、セドリック、ハンバー
ジョージ、ブランチ、イーワン
ジェームズ、アンガス、ベル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40347948&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JPS6253920(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of JPS6253920A publication Critical patent/JPS6253920A/ja
Publication of JPH0324447B2 publication Critical patent/JPH0324447B2/ja
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
JP61147996A 1985-06-25 1986-06-24 医薬 Granted JPS6253920A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB858516083A GB8516083D0 (en) 1985-06-25 1985-06-25 Heterocyclic compounds
GB8516083 1985-06-25
GB868628474A GB8628474D0 (en) 1985-06-25 1986-11-28 Pharmaceutical compositions

Publications (2)

Publication Number Publication Date
JPS6253920A true JPS6253920A (ja) 1987-03-09
JPH0324447B2 JPH0324447B2 (enExample) 1991-04-03

Family

ID=40347948

Family Applications (2)

Application Number Title Priority Date Filing Date
JP61147996A Granted JPS6253920A (ja) 1985-06-25 1986-06-24 医薬
JP62299653A Pending JPS63198623A (ja) 1985-06-25 1987-11-27 医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP62299653A Pending JPS63198623A (ja) 1985-06-25 1987-11-27 医薬組成物

Country Status (22)

Country Link
US (2) US4753789A (enExample)
EP (2) EP0431443A3 (enExample)
JP (2) JPS6253920A (enExample)
AT (2) ATE134510T1 (enExample)
AU (2) AU609028B2 (enExample)
BE (1) BE1002249A4 (enExample)
CA (1) CA1296637C (enExample)
CH (1) CH672068A5 (enExample)
CY (1) CY2000A (enExample)
DE (2) DE3650488T2 (enExample)
DK (1) DK624687A (enExample)
FR (1) FR2613934B1 (enExample)
GB (3) GB8516083D0 (enExample)
HK (1) HK82597A (enExample)
IE (1) IE60908B1 (enExample)
IL (1) IL84638A (enExample)
IT (1) IT1211937B (enExample)
NL (1) NL8702853A (enExample)
NZ (1) NZ222743A (enExample)
SE (1) SE8704747L (enExample)
SG (1) SG43311A1 (enExample)
ZA (1) ZA878927B (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61212521A (ja) * 1985-03-14 1986-09-20 ビーチヤム・グループ・ピーエルシー 医薬組成物
US4971651A (en) * 1990-02-05 1990-11-20 Hitachi, Ltd. Microwave plasma processing method and apparatus
US5003152A (en) * 1987-04-27 1991-03-26 Nippon Telegraph And Telephone Corporation Microwave transforming method and plasma processing
US8075733B2 (en) 2008-08-25 2011-12-13 Hitachi High-Technologies Corporation Plasma processing apparatus

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5578628A (en) * 1985-06-25 1996-11-26 Glaxo Group Limited Medicaments for the treatment of nausea and vomiting
GB8516083D0 (en) * 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
GB8627909D0 (en) * 1986-11-21 1986-12-31 Glaxo Group Ltd Medicaments
US5330982A (en) * 1986-12-17 1994-07-19 Glaxo Group Limited Pharmaceutical composition containing a 5-HT receptor antagonist and an H+ K+ Atpase inhibitor and a method of treating gastrointestingal disorders therewith
GB8630079D0 (en) * 1986-12-17 1987-01-28 Glaxo Group Ltd Medicaments
PH25025A (en) * 1986-12-17 1991-01-28 Glaxo Group Ltd A method of treating dementia and other cognitive disorders using 1,2,3,9-tetrahydro-9-methyl-3-((2-methyl-1h-imidazol-1-yl)methyl)-4h-carbazol-4-one
GB8630080D0 (en) * 1986-12-17 1987-01-28 Glaxo Group Ltd Medicaments
GB8630071D0 (en) * 1986-12-17 1987-01-28 Glaxo Group Ltd Medicaments
US4943428A (en) * 1987-07-10 1990-07-24 Wright State University Stimulation of serotonin-1A receptors in mammals to alleviate motion sickness and emesis induced by chemical agents
DE3822792C2 (de) * 1987-07-11 1997-11-27 Sandoz Ag Neue Verwendung von 5HT¶3¶-Antagonisten
GB8805269D0 (en) * 1988-03-04 1988-04-07 Glaxo Group Ltd Medicaments
GB8806224D0 (en) * 1988-03-16 1988-04-13 Johnson Matthey Plc Platinum chemotherapeutic product
GB8816187D0 (en) * 1988-07-07 1988-08-10 Glaxo Group Ltd Medicaments
US5047246A (en) * 1988-09-09 1991-09-10 Bristol-Myers Company Direct compression cyclophosphamide tablet
AU627221B2 (en) * 1988-09-27 1992-08-20 Fujisawa Pharmaceutical Co., Ltd. Pyridoindole derivatives and processes for preparation thereof
GB8904182D0 (en) * 1989-02-23 1989-04-05 Glaxo Canada Pharmaceutical compositions
US5039528A (en) * 1989-12-11 1991-08-13 Olney John W EAA antagonists as anti-emetic drugs
WO1993000075A1 (en) * 1991-06-26 1993-01-07 Sepracor, Inc. Methods and compositions for treating emesis, nausea and other disorders using optically pure s(-) ondansetron
AU2295792A (en) * 1991-06-26 1993-01-25 Sepracor, Inc. Method and compositions for treating emesis, nausea and other disorders using optically pure r(+) ondansetron
ATE195867T1 (de) * 1991-09-20 2000-09-15 Glaxo Group Ltd Neue medizinische indikation für tachykinin- antagonisten
CN1118990A (zh) * 1993-03-08 1996-03-20 藤泽药品工业株式会社 治疗或预防脑血管疾病药物
GB9310756D0 (en) * 1993-05-25 1993-07-14 Glaxo Lab Sa Compositions
GB9423511D0 (en) * 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
GB9423588D0 (en) * 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
CA2371822A1 (en) 1999-03-01 2000-09-08 Sepracor Inc. Methods for treating apnea and apnea disorders using optically pure r(+)ondansetron
RU2162695C1 (ru) * 2000-07-14 2001-02-10 ООО с иностранными инвестициями "Редди-Биомед лимитед" Способ получения ондансетрона гидрохлорида дигидрата, субстанция и фармацевтический препарат
KR100434390B1 (ko) * 2001-04-20 2004-06-04 안국약품 주식회사 1,2,3,9-테트라히드로-9-메틸-3-[(2-메틸-1ｈ-이미다졸-1-일)메틸]-4ｈ-카바졸-4-온을 유효성분으로 하는 비강분무용조성물
CA2505990C (en) * 2002-11-15 2009-05-19 Helsinn Healthcare S.A. Palonosetron for the treatment of chemotherapy-induced emesis
JP2006516977A (ja) * 2003-01-13 2006-07-13 ダイノゲン ファーマシューティカルズ，インコーポレイテッド 悪心、嘔吐、レッチング、またはそれらの任意の組み合わせの治療方法
US8598219B2 (en) 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
JO2735B1 (en) * 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formulations of palonosetron
MY143789A (en) 2003-02-18 2011-07-15 Helsinn Healthcare Sa Use of palonosetron treating post- operative nausea and vomiting
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
US20060167072A1 (en) * 2004-01-30 2006-07-27 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
US7288660B2 (en) * 2004-05-07 2007-10-30 Taro Pharmaceutical Industries Limited Process for preparing ondansetron hydrochloride dihydrate having a defined particle size
US20060068010A1 (en) * 2004-09-30 2006-03-30 Stephen Turner Method for improving the bioavailability of orally delivered therapeutics
WO2006105117A2 (en) * 2005-03-28 2006-10-05 Dynogen Pharmaceuticals, Inc. Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
NZ576237A (en) * 2006-10-24 2011-12-22 Helsinn Healthcare Sa Soft capsules comprising palonosetron hydrochloride having improved stability and bioavailability
JP2013515782A (ja) 2009-12-28 2013-05-09 モノソル アールエックス リミテッド ライアビリティ カンパニー オンダンセトロンを含む経口投与可能なフィルム製剤
MX342993B (es) 2013-04-25 2016-10-13 Inst Mexicano Del Petróleo Proceso de obtencion de copolimeros aleatorios derivados del acido itaconico y/o sus isomeros y alquenil sulfonatos de sodio y uso del producto obtenido.
CA3071377C (en) 2017-01-09 2021-11-30 Kathleen E. Clarence-Smith Compositions and methods for improving muscle weakness in patients suffering from myasthenia gravis and other myasthenic syndromes

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0040489A1 (en) * 1980-05-17 1981-11-25 FISONS plc Mixtures, salts, packages and pharmaceutical compositions containing 5-(2-hydroxypropoxy)-4-oxo-8-propyl-4H-1-benzopyran-2-carboxylic acid or a derivative thereof and an H2 receptor antagonist antihistamine
BE894285A (fr) * 1981-09-04 1983-03-02 Glaxo Group Ltd Composition pharmaceutique contenant un medicament anti-inflammatoire et de la ranitidine ou un sel de ce compose
FR2557110B1 (fr) * 1983-12-23 1989-11-24 Sandoz Sa Nouveaux derives d'amines cycliques, leur preparation et leur utilisation comme medicaments
US4695578A (en) * 1984-01-25 1987-09-22 Glaxo Group Limited 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
SE460359B (sv) * 1984-01-25 1989-10-02 Glaxo Group Ltd 3-imidazolylmetyltetrahydrokarbazoloner, foerfarande foer framstaellning av dessa och en farmaceutisk komposition
EP0191562B1 (en) * 1985-01-23 1991-07-10 Glaxo Group Limited Tetrahydrocarbazolone derivatives
DE3688296T2 (de) * 1985-03-14 1993-11-04 Beecham Group Plc Arzneimittel zur behandlung von erbrechen.
GB8516083D0 (en) * 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
GB8630079D0 (en) * 1986-12-17 1987-01-28 Glaxo Group Ltd Medicaments

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61212521A (ja) * 1985-03-14 1986-09-20 ビーチヤム・グループ・ピーエルシー 医薬組成物
US5003152A (en) * 1987-04-27 1991-03-26 Nippon Telegraph And Telephone Corporation Microwave transforming method and plasma processing
US4971651A (en) * 1990-02-05 1990-11-20 Hitachi, Ltd. Microwave plasma processing method and apparatus
US8075733B2 (en) 2008-08-25 2011-12-13 Hitachi High-Technologies Corporation Plasma processing apparatus

Also Published As

Publication number Publication date
DK624687A (da) 1988-05-29
DE3650488D1 (de) 1996-04-04
IT8748643A0 (it) 1987-11-27
GB8628474D0 (en) 1987-01-07
AU609028B2 (en) 1991-04-26
DK624687D0 (da) 1987-11-27
EP0226266A3 (en) 1990-01-24
SG43311A1 (en) 1997-10-17
US4753789A (en) 1988-06-28
EP0226266B1 (en) 1996-02-28
CY2000A (en) 1997-12-05
AT395374B (de) 1992-12-10
NL8702853A (nl) 1988-06-16
EP0226266A2 (en) 1987-06-24
FR2613934A1 (fr) 1988-10-21
DE3740351A1 (de) 1988-06-09
IE60908B1 (en) 1994-08-24
GB8727836D0 (en) 1987-12-31
AU616386B2 (en) 1991-10-31
AU8191487A (en) 1988-06-02
JPS63198623A (ja) 1988-08-17
GB2200046A (en) 1988-07-27
CH672068A5 (enExample) 1989-10-31
NZ222743A (en) 1991-09-25
GB2200046B (en) 1990-09-26
IL84638A (en) 1992-05-25
CA1296637C (en) 1992-03-03
IE873230L (en) 1988-05-28
EP0431443A3 (en) 1991-09-18
ATA312587A (de) 1992-05-15
EP0431443A2 (en) 1991-06-12
SE8704747L (sv) 1988-05-29
GB8516083D0 (en) 1985-07-31
FR2613934B1 (fr) 1993-07-09
JPH0324447B2 (enExample) 1991-04-03
ATE134510T1 (de) 1996-03-15
ZA878927B (en) 1988-10-26
DE3650488T2 (de) 1996-09-05
IT1211937B (it) 1989-11-08
US4929632A (en) 1990-05-29
AU6703786A (en) 1988-06-30
SE8704747D0 (sv) 1987-11-27
HK82597A (en) 1997-06-27
BE1002249A4 (fr) 1990-11-06

Similar Documents

Publication Publication Date Title
JPS6253920A (ja) 医薬
US5578632A (en) Medicaments for the treatment of gastrointestinal dysfunction
EP0349235B1 (en) Niacin and guar-gum containing composition
EP0615751B1 (en) Use of tachykinin antagonists in the treatment of emesis
EP0188081A2 (en) Use of paroxetine for the manufacture of a medicament for the treatment of obesity
IE52021B1 (en) Clonidine derivatives useful in the treatment of diarrhoea
JPS63165314A (ja) 医薬
US5240954A (en) Medicaments
AT400301B (de) Antiemetikum
US4515802A (en) Analgesic preparations
HU194736B (en) Improved process for production of antiinflammable preparative
CA2100777C (en) Pharmaceutical composition containing granisetron and dexamethasone
JPH01316319A (ja) 医薬
US3932652A (en) Antidepressant compositions
US3993778A (en) Anti-ulcerogenic pharmaceutical compositions containing a 2-amino-3,5-dibromo-benzylamine and method of use
GB2135884A (en) Analgesic preparations containing tizanidine and paracetamol
JP2002265354A (ja) 抗ピロリ菌剤組成物
CN115429797A (zh) 一种含氧氯吡格雷或其盐的组合物及其制备
EA003584B1 (ru) Способ стимуляции отказа от курения или его снижения или предупреждения возобновления курения и применение пароксетина или его фармацевтически приемлемых солей или сольватов для получения лекарственного средства
CN116570593A (zh) 一种防止卵巢早衰的药物及其用途
EP0652877A1 (en) Methanesulphonate
KR20250122522A (ko) (R)-1-(1-아크릴로일피페리딘-3-일)-4-아미노-3-(4-페녹시페닐)-1H-이미다조[4,5-c]피리딘-2(3H)-온의약물 제형
EP1884241A1 (en) A oral preparation comprising dyclonine hydrochloride
US5153216A (en) Method for treating chest pain
DE1793384A1 (de) 1-Amino-adamantanderivate

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term